H. Lundbeck (LUN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
9M revenue rose 13% CER (9% DKK) to DKK 20,191m; adjusted EBITDA increased 19% CER to DKK 7,026m, led by Vyepti and Rexulti. Excluding a DKK 470m partner-market inventory build, revenue grew 11% CER and adjusted EBITDA 12% CER.
Strong earnings and cash generation supported raised FY 2026 guidance; net debt/EBITDA fell to 0.7x from 1.3x.
Financial highlights
9M gross profit was DKK 16,493m, up 11% CER; gross margin was 81.7% and adjusted gross margin 86.6%, down 2.0 and 1.2 percentage points, respectively.
9M EBIT rose 21% CER (13% DKK) to DKK 5,409m; net profit increased 30% to DKK 4,073m and adjusted net profit rose 25% to DKK 5,369m.
9M adjusted EBITDA margin was 34.8%, up from 33.8%; excluding the inventory-build gross-profit impact, growth was 12% CER and margin was 33.5%.
Q3 revenue was DKK 6,603m, up 7% CER; adjusted EBITDA rose 17% CER to DKK 2,261m, with a 34.2% margin. EBIT increased 10% DKK to DKK 1,756m.
Q3 gross margin was 82.9% versus 86.5%; adjusted gross margin was 86.6% versus 86.3%.
Outlook and guidance
FY 2026 revenue growth guidance rose to 11%–12% CER from 7%–9%; adjusted EBITDA growth guidance rose to 15%–19% CER from 8%–14%.
Guidance includes adjusted gross margin of 86%–87%, R&D costs of DKK 5.6–5.7bn, net financial expense of ~DKK 200m and net debt of DKK 4.0–5.0bn.
Q4 growth is expected to moderate as the DKK 470m partner inventory build does not recur; U.S. Trintellix generic entry in December and increased Rexulti competition are expected to weigh on growth.
2027 mid-term targets remain mid-single-digit organic revenue CAGR for 2023–2027 and adjusted EBITDA margin above 30%, excluding business development activities; Scale phase priorities include migraine, neuro-rare launches, partnerships and AI capabilities.
Latest events from H. Lundbeck
- Upgraded guidance and late-stage catalysts support the 2027–2029 scale phase.LUN
Jefferies Global Healthcare Conference - Vyepti-led growth lifted 9M results and FY 2026 guidance as leverage fell to 0.7x.LUN
Q3 2026 - Strategic-brand growth and pipeline investment support 2026 growth amid generic headwinds.LUN
Q4 2025 - Strong growth, innovation, and capital discipline drive long-term value and shareholder returns.LUN
Investor update - H1 2026 saw 16% CER revenue growth, strong brand and pipeline momentum, and guidance maintained.LUN
Q2 2026 - H1 2026 revenue up 16% CER, strong cash flow, and robust growth from Vyepti and Rexulti.LUN
Q2 2026 - Bocunebart showed strong efficacy and safety in migraine prevention, advancing to Phase III.LUN
Study update - Q1 2026 saw 21% CER revenue growth, margin expansion, and upgraded full-year guidance.LUN
Q1 2026 - Transformative year with late-stage pipeline advances and disciplined capital allocation.LUN
43rd Annual J.P. Morgan Healthcare Conference